Pre-Open Stock Movers 12/07: (KODK) (CKH) Higher; (RIDE) (XPEV) (JKS) Lower (more...)

JinkoSolar (JKS) Announces Proposed At-the-Market ADS Offering Up to $100M

JinkoSolar Holding Co., Ltd. (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that its board of directors has approved its proposed equity offering through an at-the-market equity offering program. The Company is preparing relevant... More

HOOKIPA Pharma Inc. (HOOK) Prices 3.4M Share Common Offering at $11.75/Sh

HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the Offering). The public offering price of each share of common stock is $11.75... More

ATARA Biotherapeutics (ATRA) Prices 5.102M Share Common Offering at $24.50/Sh

Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock at a price to the public of $24.50 per share and, to... More

Kura Oncology (KURA) Prices 8.11M Share Common Offering at $37/Sh

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public... More

Gilead Sciences (GILD) Announces Jeffrey A. Bluestone to Board

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Jeffrey A. Bluestone, PhD, has been appointed to the companys Board of Directors.

Dr. Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology at the University of California San Francisco. He is an international leader in the field of immunotherapy and has published more than 500 papers over... More